Insulin treatment and cardiovascular disease; friend or foe? A point of view

Diabetic Medicine

Volumn 22, Issue 2, 2005, Pages 118-126

  Muis, M J ^a   Bots, M L ^a   Grobbee, D E ^a   Stolk, R P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cardiovascular diseases; Diabetes mellitus; Hyperinsulinaemia; Insulin therapy; Insulin dependent; Non insulin dependent

Indexed keywords

INSULIN; PLACEBO; SULFONYLUREA DERIVATIVE;

ADOLESCENT; ADULT; AGED; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EXPOSURE; GLUCOSE HOMEOSTASIS; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; VASCULAR ENDOTHELIUM;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INSULIN; RANDOMIZED CONTROLLED TRIALS;

EID: 13444283628     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2004.01416.x     Document Type: Review

References (77)

1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
2. Krolewski AS, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987; 59: 750-755.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
5. Scherbaum WA. Insulin therapy in Europe. Diabetes Metab Res Rev 2002; 18: S50-S56.
6. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial [published erratum appears in JAMA 1998 November 4; 280: 1484] [see comments]. JAMA 1998; 280: 140-146.
7. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial [published erratum appears in JAMA 1998 November 4; 280: 1484] [see comments]. JAMA 1998; 280: 140-146.
8. Stout RW. Insulin and atheroma. 20-yr perspective. Diabetes Care 1990; 13: 631-654.
9. Ruige JB, Assendelft WJ, Dekker JM, Kostense PJ, Heine RJ, Bouter LM. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 1998; 97: 996-1001.
10. Cusi K, Cunningham GR, Comstock JP. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Diabetes Care 1995; 18: 843-851.
11. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. Diabetes Care 1993; 16: 21-31.
12. Jacobs MA, Keulen ET, Kanc K, Casteleijn S, Scheffer P, Deville W et al. Metabolic efficacy of preprandial administration of Lys(B28), Pro(B29) human insulin analog in IDDM patients. A comparison with human regular insulin during a three-meal test period. Diabetes Care 1997; 20: 1279-1286.
13. Horwitz DL, Starr JI, Mako ME, Blackard WG, Rubenstein AH. Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood. J Clin Invest 1975; 55: 1278-1283.
14. Fontbonne A, Tchobroutsky G, Eschwege E, Richards JL, Claude JR, Rosselin GE. Coronary heart disease mortality risk: plasma insulin level is a more sensitive marker than hypertension or abnormal glucose tolerance in overweight males. The Paris Prospective Study. Int J Obes 1988; 12: 557-565.
15. Pyorala M, Miettinen H, Laakso M, Pyorala K. Plasma insulin and all-cause, cardiovascular, and noncardiovascular mortality: the 22-year follow-up results of the Helsinki Policemen Study. Diabetes Care 2000; 23: 1097-1102.
16. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979; 2: 154-160.
17. Pyorala K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 1/2-year follow-up of the Helsinki Policemen Study population. Acta Med Scand Suppl 1985; 701: 38-52.
18. Liu QZ, Knowler WC, Nelson RG, Saad MF, Charles MA, Liebow IM et al. Insulin treatment, endogenous insulin concentration, and ECG abnormalities in diabetic Pima Indians. Cross-sectional and prospective analyses. Diabetes 1992; 41: 1141-1150.
19. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S et al. Hyperinsulinemia as an independent risk factor for ischemie heart disease. N Engl J Med 1996; 334: 952-957.
20. Orchard TJ, Eichner J, Kuller LH, Becker DJ, McCallum LM, Grandits GA. Insulin as a predictor of coronary heart disease: interaction with apolipoprotein E phenotype. A report from the Multiple Risk Factor Intervention Trial. Ann Epidemiol 1994; 4: 40-45.
21. Fontbonne A, Charles MA, Thibult N, Richard JL, Claude JR, Warnet JM et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 1991; 34: 356-361
22. Collins VR, Dowse GK, Zimmet PZ, Tuomilehto J, Alberti KG, Gareeboo H et al. Serum insulin and ECG abnormalities suggesting coronary heart disease in the populations of Mauritius and Nauru: cross-sectional and longitudinal associations. J Clin Epidemiol 1993; 46: 1373-1393.
23. Hargreaves AD, Logan RL, Elton RA, Buchanan KD, Oliver MF, Riemersma RA. Glucose tolerance, plasma insulin, HDL cholesterol and obesity: 12-year follow-up and development of coronary heart disease in Edinburgh men. Atherosclerosis 1992; 94: 51-69.
24. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. Hyperinsulinemic microalbuminuria. A new risk indicator for coronary heart disease. Circulation 1995; 91: 831-837.
25. Moller LF, Jespersen J. Fasting serum insulin levels and coronary heart disease in a Danish cohort: 17-year follow-up. J Cardiovasc Risk 1995; 2: 235-240.
26. Perry IJ, Wannamethee SG, Whincup PH, Shaper AG, Walker MK, Alberti KG. Serum insulin and incident coronary heart disease in middle-aged British men. Am J Epidemiol 1996; 144: 224-234.
27. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002; 19: 708-723.
28. Laight DW, Carrier MJ, Anggard EE. Endothelial cell dysfunction and the pathogenesis of diabetic macroangiopathy. Diabetes Metab Res Rev 1999; 15: 274-282.
29. Plenz G, Robenek H. Monocytes/macrophages in atherosclerosis. Eur Cytokine Netw 1998; 9: 701-703.
30. Aljada A, Dandona P. Effect of insulin on human aortic endothelial nitric oxide synthase. Metabolism 2000; 49: 147-150.
31. Zeng G, Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996; 98: 894-898.
32. Aljada A, Ghanim H, Saadeh R, Dandona P. Insulin inhibits NF-kappaB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab 2001; 86: 450-453.
33. Aljada A, Saadeh R, Assian E, Ghanim H, Dandona P. Insulin inhibits the expression of intercellular adhesion molecule-1 by human aortic endothelial cells through stimulation of nitric oxide. J Clin Endocrinol Metab 2000; 85: 2572-2575.
34. Hattori Y, Kasai K, Nakamura T, Emoto T, Shimoda S. Effect of glucose and insulin on immunoreactive endothelin-1 release from cultured porcine aortic endothelial cells. Metabolism 1991; 40: 165-169.
35. Hsueh WA, Law RE. Insulin signaling in the arterial wall. Am J Cardiol 1999; 84: 21J-24J.
36. Stout RW. Development of vascular lesions in insulin-treated animals fed a normal diet. Br Med J 1970; 3: 685-687.
37. Stout RW, Buchanan KD, Vallance-Owen J. The relationship of arterial disease and glucagon metabolism in insulin-treated chickens. Atherosclerosis 1973; 18: 153-162.
38. Nordestgaard BG, Agerholm-Larsen B, Stender S. Effect of exogenous hyperinsulinaemia on atherogenesis in cholesterol-fed rabbits. Diabetologia 1997; 40: 512-520.
39. Abramson DI, Schkloven N, Margolis MN, Mirsky IA. Influence of massive doses of insulin on peripheral blood flow in man. Am J Physiol 1939; 128: 124-132.
40. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994; 94: 2511-2515.
41. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1994; 94: 1172-1179.
42. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 1990; 85: 1844-1852.
43. Dandona P, Aljada A, Mohanty P. The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 2002; 45: 924-930.
44. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001; 86: 3257-3265.
45. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981; 30: 219-225.
46. Berne C, Fagius J, Pollare T, Hjemdahl P. The sympathetic response to euglycaemic hyperinsulinaemia. Evidence from microelectrode nerve recordings in healthy subjects. Diabetologia 1992; 35: 873-879.
47. Vollenweider P, Randin D, Tappy L, Jequier E, Nicod P, Scherrer U. Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. J Clin Invest 1994; 93: 2365-2371.
48. Scherrer U, Sartori C. Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 1997; 96: 4104-4113.
49. Cardillo C, Nambi SS, Kilcoyne CM, Choucair WK, Katz A, Quon MJ et al. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation 1999; 100: 820-825.
50. Arcaro G, Cretti A, Balzano S, Lechi A, Muggeo M, Bonora E et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 2002; 105: 576-582.
51. Arcaro G, Solini A, Monauni T, Cretti A, Brunato B, Lechi A et al. ACE genotype and endothelium-dependent vasodilation of conduit arteries and forearm microcirculation in humans. Arterioscler Thromb Vasc Biol 2001; 21: 1313-1319.
52. Leonetti F, Iozzo P, Giaccari A, Sbraccia P, Buongiorno A, Tamburrano G et al. Absence of clinically overt atherosclerotic vascular disease and adverse changes in cardiovascular risk factors in 70 patients with insulinoma. J Endocrinol Invest 1993; 16: 875-880.
53. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003; 348: 645-650.
54. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003; 348: 2294-2303.
55. Diabetes Control and Complications Trial. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995; 75: 894-903.
56. Brinchmann-Hansen O, Dahl-Jorgensen K, Sandvik L, Hanssen KF. Blood glucose concentrations and progression of diabetic retinopathy. The seven year results of the Oslo study. BMJ 1992; 304: 19-22.
57. Feldt-Rasmussen B, Mathiesen ER, Jensen T, Lauritzen T, Deckert T. Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies. Diabetologia 1991; 34: 164-170.
58. Holman RR, Dornan TL, Mayon-White V, Howard-Williams J, Orde-Peckar C, Jenkins L et al. Prevention of deterioration of renal and sensory-nerve function by more intensive management of insulin-dependent diabetic patients. A two-year randomised prospective study. Lancet 1983; 1: 204-208.
59. Lawson ML, Gerstein HC, Tsui E, Zinman B. Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis. Diabetes Care 1999; 22: B35-B39.
60. Reichard P, Pihl M. Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes 1994; 43: 313-317.
61. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VIII. Evaluation of insulin therapy: final report. Diabetes 1982; 31 (Suppl. 1): S1-81.
62. Abraira C, Colwell J, Nuttall F, Sawin CT, Henderson W, Comstock JP et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 1997; 157: 181-188.
63. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-65.
64. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction, long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999; 99: 2626-2632.
65. Sundell J, Nuutila P, Laine H, Luotolahti M, Kalliokoski K, Raitakari O et al. Dose-dependent vasodilating effects of insulin on adenosine-stimulated myocardial blood flow. Diabetes 2002; 51: 1125-1130.
66. Hayford JT, Thompson RG. Free and total insulin integrated concentrations in insulin dependent diabetes. Metabolism 1982; 31: 387-397.
67. Rizza RA, Gerich JE, Haymond MW, Westland RE, Hall LD, Clemens AH et al. Control of blood sugar in insulin-dependent diabetes: comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion, and intensified conventional insulin therapy. N Engl J Med 1980; 303: 1313-1318.
68. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys (B28), Pro (B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402.
69. Grobbee DE, Hoes AW. Confounding and indication for treatment in evaluation of drug treatment for hypertension. BMJ 1997; 315: 1151-1154.
70. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Diabetes 1999; 48: 383-390.
71. Nelson RG, Sievers ML, Knowler WC, Swinburn BA, Pettitt DJ, Saad MF et al. Low incidence of fatal coronary heart disease in Pima Indians despite high prevalence of non-insulin-dependent diabetes. Circulation 1990; 81: 987-995.
72. Janka HU, Ziegler AG, Standl E, Mehnert H. Daily insulin dose as a predictor of macrovascular disease in insulin treated non-insulin-dependent diabetics. Diabetes Metab 1987; 13: 359-364.
73. Kleinman JC, Donahue RP, Harris MI, Finucane FF, Madans JH, Brock DB. Mortality among diabetics in a national sample. Am J Epidemiol 1988; 128: 389-401.
74. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001; 24: 1614-1619.
75. Bruno G, Merletti F, Boffetta P, Cavallo-Perin P, Bargero G, Gallone G et al. Impact of glycaemic control, hypertension and insulin treatment on general and cause-specific mortality: an Italian population-based cohort of type II (non-insulin-dependent) diabetes mellitus. Diabetologia 1999; 42: 297-301.
76. Saito I, Folsom AR, Brancati FL, Duncan BB, Chambless LE, McGovern PG. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Intern Med 2000; 133: 81-91.
77. Abraira C, McGuire DK. Intensive insulin therapy in patients with type 2 diabetes: implications of the Veterans affairs (VA CSDM) feasibility trial. Am Heart J 1999; 138: S360-S365.